Gubra A/S (GUBRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gubra A/S (GUBRA) has a cash flow conversion efficiency ratio of -0.519x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-594.98 Million ≈ $-93.09 Million USD) by net assets (Dkr1.15 Billion ≈ $179.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gubra A/S defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Gubra A/S - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Gubra A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gubra A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gubra A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beken Corp
SHG:603068
|
0.014x |
|
Flotek Industries Inc
NYSE:FTK
|
0.000x |
|
Sanofi India Limited
NSE:SANOFI
|
0.585x |
|
LX International Corp
KO:001120
|
0.074x |
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
0.000x |
|
Barclays PLC
LSE:BARC
|
0.243x |
|
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
|
N/A |
|
SeAH Bestee
KO:001430
|
0.007x |
Annual Cash Flow Conversion Efficiency for Gubra A/S (2020–2025)
The table below shows the annual cash flow conversion efficiency of Gubra A/S from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see GUBRA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr1.15 Billion ≈ $179.29 Million |
Dkr1.71 Billion ≈ $267.91 Million |
1.494x | +13314.80% |
| 2024-12-31 | Dkr450.57 Million ≈ $70.50 Million |
Dkr5.02 Million ≈ $785.26K |
0.011x | +110.81% |
| 2023-12-31 | Dkr479.66 Million ≈ $75.05 Million |
Dkr-49.42 Million ≈ $-7.73 Million |
-0.103x | -145.80% |
| 2022-12-31 | Dkr108.21 Million ≈ $16.93 Million |
Dkr24.34 Million ≈ $3.81 Million |
0.225x | -61.51% |
| 2021-12-31 | Dkr151.46 Million ≈ $23.70 Million |
Dkr88.51 Million ≈ $13.85 Million |
0.584x | +41.74% |
| 2020-12-31 | Dkr80.01 Million ≈ $12.52 Million |
Dkr32.99 Million ≈ $5.16 Million |
0.412x | -- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more